New York, NY, United States of America

H Umit Kaniskan

This inventor holds 1 USPTO granted patent and 6 published patent applications and 1 EPO patent. Top assignee: Icahn School of Medicine at Mount Sinai. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: H Umit Kaniskan. Retrieved from https://idiyas.com/inventor/h-umit-kaniskan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: H Umit Kaniskan: Innovator in HPK1 Degradation Compounds

Introduction

H Umit Kaniskan is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of biomedical research, particularly in the development of compounds that target Hematopoietic Progenitor Kinase 1 (HPK1). His innovative work has the potential to impact the treatment of various HPK1-mediated diseases.

Latest Patents

H Umit Kaniskan holds a patent for "Heterobifunctional compounds as degraders of HPK1." This patent discloses compounds that include a HPK1 ligand, a degradation/disruption tag, and a linker. These compounds are designed for use in the treatment of diseases associated with HPK1, showcasing Kaniskan's commitment to advancing medical science.

Career Highlights

Kaniskan is affiliated with the Icahn School of Medicine at Mount Sinai, where he conducts his research. His work is characterized by a focus on innovative solutions to complex medical challenges. With a patent portfolio that includes 1 patent, he continues to push the boundaries of what is possible in his field.

Collaborations

Throughout his career, Kaniskan has collaborated with esteemed colleagues such as Jian Jin and Steven Burakoff. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic strategies.

Conclusion

H Umit Kaniskan is a dedicated inventor whose work in HPK1 degradation compounds holds promise for the future of medical treatments. His contributions to the field exemplify the importance of innovation in addressing complex health issues.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…